Jason David Sawyer - 15 Apr 2026 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Reporting relationship: Director
Issuer ticker: LIXT
Reported as of: 15 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Apr 2026, 16:15:37 UTC
Prior SEC filing: 01 Jul 2026
Next SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Jason Sawyer

Key filing fact

Jason David Sawyer filed Form 4 for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) on 17 Apr 2026.

Key facts

This page summarizes Jason David Sawyer's Form 4 filing for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Apr 2026, 16:15.

Change

Previous filing in this sequence was filed on 01 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002076325 Primary reporting owner

Sawyer Jason David

Relationship: Director
Address: 433 PLAZA REAL.,, SUITE 275, BOCA RATON
Signature: /s/ Jason Sawyer
Signature date: 17 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LIXT transaction

Common Stock

Award

Transaction value
Shares: +25,000
Change %
Price
Shares after: 25,000
Date: 15 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LIXT transaction Derivative

Options to Purchase Common Stock

Disposed to Issuer

Transaction value
Shares: -25,000
Change %: -100%
Price
Shares after: 0
Date: 15 Apr 2026
Ownership: Direct
Underlying class: Common
Underlying amount: 25,000
Exercise price: $3.59
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On April 15, 2026, the Issuer canceled, pursuant to that certain Stock Option Cancellation Agreement dated April 15, 2026 between the Issuer and the Reporting Person, the 25,000 options (the "Options") granted to the Reporting Person on August 15, 2025. In exchange for the Options, the Reporting Person received 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the applicable award agreement dated April 15, 2026 and the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The 25,000 RSUs vest immediately upon grant.

Footnote F2

The canceled Options provided for vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested.